Sage Therapeutics’ (NASDAQ:SAGE) Buy Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their buy rating on shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) in a research report sent to investors on Wednesday, October 18th. Royal Bank Of Canada currently has a $117.00 price objective on the biopharmaceutical company’s stock.

SAGE has been the subject of several other reports. Stifel Nicolaus reiterated a buy rating and set a $91.00 price objective (down from $104.00) on shares of Sage Therapeutics in a research report on Wednesday, September 13th. J P Morgan Chase & Co reiterated a buy rating on shares of Sage Therapeutics in a research report on Thursday, August 31st. Cowen and Company reiterated a buy rating and set a $100.00 price objective on shares of Sage Therapeutics in a research report on Friday, August 4th. Goldman Sachs Group, Inc. (The) reiterated a buy rating and set a $87.00 price objective on shares of Sage Therapeutics in a research report on Friday, October 6th. Finally, BidaskClub downgraded Sage Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 23rd. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $86.50.

Shares of Sage Therapeutics (NASDAQ SAGE) traded up 5.71% during trading on Wednesday, hitting $64.19. The stock had a trading volume of 494,271 shares. The company’s 50 day moving average price is $64.92 and its 200 day moving average price is $73.79. The stock’s market cap is $2.40 billion. Sage Therapeutics has a 12 month low of $38.30 and a 12 month high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same quarter in the prior year, the company earned ($1.08) earnings per share. Equities research analysts expect that Sage Therapeutics will post ($7.40) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sage Therapeutics’ (NASDAQ:SAGE) Buy Rating Reaffirmed at Royal Bank Of Canada” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/sage-therapeutics-inc-sage-given-buy-rating-at-royal-bank-of-canada.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in shares of Sage Therapeutics by 1.1% in the first quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock worth $400,000 after acquiring an additional 62 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 138 shares during the last quarter. Keybank National Association OH increased its stake in shares of Sage Therapeutics by 10.6% in the second quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Sage Therapeutics by 19.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 497 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in Sage Therapeutics by 0.9% in the second quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock worth $4,723,000 after purchasing an additional 552 shares in the last quarter.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply